Overview

A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study

Status:
Completed

Trial end date:
2017-04-28

Target enrollment:

Participant gender:

Summary

The purposes of this study are to investigate the effect of intraocular pressure lowering efficacy and safety of DE-117 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension who are non-/low-responders to latanoprost ophthalmic solution.

Phase:

Phase 3

Details

Lead Sponsor:

Santen Pharmaceutical Co., Ltd.

Treatments:

Latanoprost
Ophthalmic Solutions
Pharmaceutical Solutions